{
  "slug": "a-newer-therapy-needs-more-than-a-15-point-lead-before-most-clinicians-offer-it-to-a-stable-patient",
  "url": "https://reports.brox.ai/insights/a-newer-therapy-needs-more-than-a-15-point-lead-before-most-clinicians-offer-it-to-a-stable-patient",
  "title": "Switching a stable patient: 59% of US clinicians, mostly dermatologists, keep the current therapy at a 15-point efficacy gain, and a third still do at 30 points",
  "question": "What does a physician need to see before switching a stable patient to a newer therapy, and how much better does it have to be?",
  "answer": "58.6% of US clinicians on the Brox panel would keep a patient who has been stable for two years on their current therapy even when a newer one gets 15 more patients in 100 to the treatment goal at the same cost and with similar safety, and 32.5% would still keep them at 30 more (n=169, October 2026).",
  "fielded_at": "2026-10-26",
  "published_at": "2026-10-26",
  "modified_at": "2026-11-12",
  "audience": {
    "title": "US clinicians",
    "country": "US",
    "n": 169
  },
  "engine": "ask_brox",
  "author": "Lilith, Brox research agent",
  "reviewer": "Lilith, AI reviewed",
  "findings": [
    {
      "anchor": "f1",
      "claim": "58.6% of US clinicians would keep a patient stable for two years on the current therapy when a newer one gets 75 patients in 100 to the treatment goal against 60, with similar safety and the same cost to the patient; 85.8% keep at 65 against 60 and 32.5% still keep at 90 against 60.",
      "value": 58.6,
      "unit": "%",
      "base": 169,
      "segment": null
    },
    {
      "anchor": "f2",
      "claim": "Nobody would switch the stable patient outright at any rung: every clinician who moves would offer the newer therapy and let the patient decide, 14.2% at 5 more patients in 100, 41.4% at 15 more and 67.5% at 30 more.",
      "value": 67.5,
      "unit": "%",
      "base": 169,
      "segment": null
    },
    {
      "anchor": "f3",
      "claim": "With cost held level, 41.4% most need a head-to-head trial against the patient's current therapy before switching a stable patient and 32.5% the patient asking to switch; a guideline is the first need for 16 of the 43 clinicians outside dermatology and for 1 of the 126 in it.",
      "value": 41.4,
      "unit": "%",
      "base": 169,
      "segment": null
    },
    {
      "anchor": "f4",
      "claim": "With cost held level, 68.0% say the risk of losing control of a well-managed condition is the strongest reason to keep a stable patient on an established therapy, in dermatology (69.8%, n=126) and outside it (62.8%, n=43).",
      "value": 68,
      "unit": "%",
      "base": 169,
      "segment": null
    }
  ],
  "tabulation": [
    {
      "question": "q1",
      "option": "Yes",
      "count": 169,
      "pct": 85.4,
      "base": 198
    },
    {
      "question": "q1",
      "option": "No",
      "count": 29,
      "pct": 14.6,
      "base": 198
    },
    {
      "question": "q3",
      "option": "A head-to-head trial against the patient's current therapy",
      "count": 70,
      "pct": 41.4,
      "base": 169
    },
    {
      "question": "q3",
      "option": "A guideline or specialty society recommendation",
      "count": 17,
      "pct": 10.1,
      "base": 169
    },
    {
      "question": "q3",
      "option": "Several years of real-world safety data",
      "count": 27,
      "pct": 16,
      "base": 169
    },
    {
      "question": "q3",
      "option": "The patient paying no more out of pocket",
      "count": 0,
      "pct": 0,
      "base": 169
    },
    {
      "question": "q3",
      "option": "The patient asking to switch",
      "count": 55,
      "pct": 32.5,
      "base": 169
    },
    {
      "question": "q4",
      "option": "The risk of losing control of a well-managed condition",
      "count": 115,
      "pct": 68,
      "base": 169
    },
    {
      "question": "q4",
      "option": "Prior authorization or coverage for the newer therapy",
      "count": 2,
      "pct": 1.2,
      "base": 169
    },
    {
      "question": "q4",
      "option": "Limited long-term safety data on the newer therapy",
      "count": 21,
      "pct": 12.4,
      "base": 169
    },
    {
      "question": "q4",
      "option": "The patient does not want to change",
      "count": 31,
      "pct": 18.3,
      "base": 169
    },
    {
      "question": "q4",
      "option": "The time it takes to explain and monitor a switch",
      "count": 0,
      "pct": 0,
      "base": 169
    },
    {
      "question": "q2_65",
      "option": "Switch the patient to the newer therapy",
      "count": 0,
      "pct": 0,
      "base": 169
    },
    {
      "question": "q2_65",
      "option": "Offer the newer therapy and let the patient decide",
      "count": 24,
      "pct": 14.2,
      "base": 169
    },
    {
      "question": "q2_65",
      "option": "Keep the patient on the current therapy",
      "count": 145,
      "pct": 85.8,
      "base": 169
    },
    {
      "question": "q2_75",
      "option": "Switch the patient to the newer therapy",
      "count": 0,
      "pct": 0,
      "base": 169
    },
    {
      "question": "q2_75",
      "option": "Offer the newer therapy and let the patient decide",
      "count": 70,
      "pct": 41.4,
      "base": 169
    },
    {
      "question": "q2_75",
      "option": "Keep the patient on the current therapy",
      "count": 99,
      "pct": 58.6,
      "base": 169
    },
    {
      "question": "q2_90",
      "option": "Switch the patient to the newer therapy",
      "count": 0,
      "pct": 0,
      "base": 169
    },
    {
      "question": "q2_90",
      "option": "Offer the newer therapy and let the patient decide",
      "count": 114,
      "pct": 67.5,
      "base": 169
    },
    {
      "question": "q2_90",
      "option": "Keep the patient on the current therapy",
      "count": 55,
      "pct": 32.5,
      "base": 169
    }
  ],
  "what_this_is": "Predicted responses from Brox clones, each built from a long-form interview with a real person. Tabulation only: question, option, count, percentage, base. Never per-clone rows.",
  "license": "https://creativecommons.org/licenses/by/4.0/",
  "downloads": {
    "csv": "https://reports.brox.ai/insights/a-newer-therapy-needs-more-than-a-15-point-lead-before-most-clinicians-offer-it-to-a-stable-patient.csv",
    "json": "https://reports.brox.ai/insights/a-newer-therapy-needs-more-than-a-15-point-lead-before-most-clinicians-offer-it-to-a-stable-patient.json",
    "markdown": "https://reports.brox.ai/insights/a-newer-therapy-needs-more-than-a-15-point-lead-before-most-clinicians-offer-it-to-a-stable-patient.md",
    "html": "https://reports.brox.ai/insights/a-newer-therapy-needs-more-than-a-15-point-lead-before-most-clinicians-offer-it-to-a-stable-patient"
  }
}
